Premium
Effects of DA11 in db/db Mice and Streptozotocin ‐induced Type 2 Diabetic Rat Model
Author(s) -
Kang SeChan Kang,
Yang YoonJung,
Kim Han Kyeol,
Kang NamSung,
Sohn EunHwa,
Kim SunYoung
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.lb376
Subject(s) - streptozotocin , medicine , endocrinology , triglyceride , diabetes mellitus , insulin , cholesterol
The Effects of DA11, a medicinal plant mixture developed as a pharmaceutical for the treatment of diabetes mellitus (DM), were investigated in type 2 diabetic db/db mice as well as in streptozotocin (STZ)‐induced diabetic rat models. Various doses of DA11 were administered to the db/db mice and STZ‐induced rats for 5 weeks by PO. The blood glucose levels of the diabetic control animals were increased, whereas the concentrations in DA11‐treated animals remained consistently low throughout the experiment period. Serum insulin levels were not different between control and DA11‐treated animals when measured at the end of the study. DA11 suppressed the levels of total cholesterol and triglyceride after 5 weeks in both the db/db mice and the STZ‐induced diabetic rats. In microscopic observation and immunohistochemistry, DA11 restored the insulin level. These data demonstrate that DA11 can provide beneficial effects in treating type 2 DM by lowering serum glucose levels as well as total cholesterol and triglyceride.